Neoadjuvant bevacizumab (B) and trastuzumab (T) in combination with weekly paclitaxel (P) as neoadjuvant treatment in HER2-positive breast cancer: Results from a phase II trial (AVANTHER).

Abad, María Fernández; Calvo, Isabel; Martínez, Noelia; Herrero, Mercedes; Quijano, Yolanda; Durán, Hipólito; Aranda, M. Garcia; Pereira‐Suárez, Ana Laura; López‐Ríos, Fernando; Pérez, Diego; Perea, Sofía; Hidalgo, Manuel; García-Estévez, Laura

doi:10.1200/jco.2012.30.15_suppl.602

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A single-arm phase II study of sunitinib, docetaxel, and trastuzumab in HER2positive MBC reported 16 PRs in 22 patients [107]. In the phase II AVANTHER study of neoadjuvant bevacizumab (Avastin; Genentech), a monoclonal anti-VEGF antibody, with trastuzumab and paclitaxel, pCR was achieved in 18 of 44 HER2-positive patients [108]. Another phase II study is evaluating neoadjuvant trastuzumab and chemotherapy with or without bevacizumab (NCT01367028).…”

Section: Other Targetsmentioning

confidence: 99%

Human Epidermal Growth Factor Receptor Family-Targeted Therapies in the Treatment of HER2-Overexpressing Breast Cancer

2014

View full text Add to dashboard Cite

Purpose. Chemotherapy has been tested extensively in conjunction with standard therapy in the treatment of head and neck cancer, primarily in the form of neoadjuvant chemotherapy, but few trials have shown a survival benefit. Although a few studies have suggested that adjuvant chemotherapy given after standard treatment may improve survival, to date these trials have been troubled by various problems in design and dosing. The purpose of our trial was to determine the feasibility of giving moderately intensive chemotherapy exclusively after standard therapy, and to determine whether survival appeared to be improved as measured against historical data. Methods. We used adjuvant chemotherapy in two groups of patients with squamous cell carcinoma of the head and neck: group A consisted of 46 patients with newly diagnosed stage III and IV disease, and group B consisted of 46 patients with relapsed disease having been treated with salvage surgery. In all patients, the intended adjuvant chemotherapy consisted of two cycles of combination cisplatin, bleomycin, and infusional 5‐fluorouracil (5‐FU) given three weeks apart, followed by four cycles of bolus methotrexate, 5‐FU, and bleomycin given every two weeks. Results. In group A, the two‐year survival was 72%. In group B, the two‐year survival was 58%. Conclusion. Compared to the vast majority of similarly staged patients with head and neck cancer reported in the literature, the survival of our group seemed considerably better, suggesting that a definitive randomized study testing this schedule of adjuvant chemotherapy is warranted.

show abstract

Section: Other Targetsmentioning

confidence: 99%